Other third-generation EGFR-TKIs including furmonertinib (AST2818) [33, 34], lazertinib (YH25448) [35], BPI-7711 [36], and nazartinib (EGF816) [37] have shown promising efficacies and acceptable safeties in advanced NSCLC with EGFR T790M mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.